Objective  To study the mechanism of Jianpi Yishen formula in the treatment of renal anemia based on HPLC-QQQ-MS/MS, network pharmacology, molecular docking and experimental verification.

Methods  The chemical constituents of Jianpi Yishen formula were analyzed by HPLC-QQQ-MS/MS. TCMIP v2.0 and other databases were used to predict the targets and pathways of chemical constituents and renal anemia, and the "intersection component-intersection target-pathway" connection network was drawn to predict the core targets and compounds in the treatment of renal anemia. The core targets and compounds were further validated by molecular docking and animal experiments.

Results  A total of 11 components were identified from Jianpi Yishen formula. Through Draw Venn Diagram, 81 targets in Jianpi Yishen formula related to renal anemia were screened, suggesting that AKT1、PIK3CA、EGFR、BCL2、HRAS, etc may be key targets and Salvianolic acid A, Rosmarinic acid, Rhein, Calycosin-7-glucoside and Calycosin may be key components. Molecular docking results showed that the core targets and components of network pharmacology prediction was of high reliability. Animal experiments showed that Jianpi Yishen formula significantly improved kidney injury and hematological parameters in chronic kidney disease rats and inhibited EGFR to treat renal anemia.

Conclusion Through constituents characterization and network pharmacological association analysis, molecular docking and experimental verification, the mechanism of Jianpi Yishen formula in the treatment of renal anemia by inhibiting EGFR was clarified, which can provide a basis for its clinical application.

1.Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11): 825-830. DOI: 10.7326/0003-4819-158-11-201306040-00007.

2.Li Y, Ning YC, Shen B, et al. Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019[J]. Clin Kidney J, 2023, 16(2): 312-321. DOI: 10.1093/ckj/sfac218.

3.王霞, 薛凌宇. 肾性贫血发病机制研究进展[J]. 山东第一医科大学(山东省医学科学院)学报, 2022, 43(2): 142-147. [Wang  X, Xue LY. Advances in the pathogenesis of renal anemia[J]. Journal of Shandong First Medical University & Shandong Academy of Medical Sciences, 2022, 43(2): 142-147.] DOI: 10.3969/j.issn.2097-0005.2022.02.013.

4.成水芹, 周婷婷, 张志宏, 等. 罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J]. 肾脏病与透析肾移植杂志, 2022, 31(1): 9-14. [Cheng  SQ, Zhou TT, Zhang ZH, et al. Roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis[J]. Chinese Journal of Nephrology,Dialysis & Transplantation, 2022, 31(1): 9-14.] DOI: 10.3969/j.issn.1006- 298X.2022.01.002.

5.李璐璐, 黄铁花, 卫四宝, 等. 重组人促红细胞生成素不良反应149例文献分析[J]. 中国药师, 2018, 21(3): 438-441.[Li LL, Huang TH, Wei SB, et al. Literature analysis of adverse reactions induced by recombinant human erythropoietin in 149 case re-ports[J]. Frontiers in Pharmaceutical Sciences, 2018, 21(3): 438-441.] DOI: 10.3969/j.issn.1008-049X.2018.03.016.

6.陈玲伟, 柯颖杰, 李云生, 等. 罗沙司他在ESAs治疗无效的透析患者中的应用[J]. 中国中西医结合肾病杂志, 2021, 22(11): 1011-1013. [Chen LW, Ke YJ, Li YS, et al. Application of Roxadustat in dialysis patients with ineffective ESAs therapy[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2021, 22(11): 1011-1013.] DOI: 10.3969/j.issn.1009-587X.2021.11.022.

7.赵卫红, 裴小华. 铁剂在肾性贫血的应用体会[J]. 肾脏病与透析肾移植杂志, 2018, 27(1): 52-53. [Zhao WH, Pei XH. Experiences on the application of iron agents in renal anemia[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2018, 27(1): 52-53.] DOI: 10.3969/j.issn.1006-298X.2018.01.011.

8.易铁钢, 祁爱蓉, 易无庸. 健脾益肾方治疗慢性肾衰竭62例临床观察[J]. 中国中西医结合肾病杂志, 2004, 5(3): 149-151. [Yi TG, Qi AR, Yi WY, et al. The clinical study of the Jianpiyishen fang in treating chronic renal failure[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2004, 5(3): 149-151.] DOI: 10.3969/j.issn.1009-587X.2004.03.009.

9.Wang FC, Yu HM, Huang SY, et al. Jian-Pi-Yi-Shen regulates EPO and iron recycling protein expressions in anemic rats with chronic kidney disease: accumulation of hypoxia inducible factor-2 α via ERK signaling[J]. Evid Based Complement Alternat Med, 2020, 2020: 8894257. DOI: 10.1155/2020/8894257.

10.Li CH, Huang HP, Wang R, et al. Jian-Pi-Yi-Shen formula restores iron metabolism from dysregulation in anemic rats with adenine-induced nephropathy[J]. J Ethnopharmacol, 2023, 312: 116526. DOI: 10.1016/j.jep.2023.116526.

11.Colomiere M, Findlay J, Ackland L, et al. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin[J]. Int J Biochem Cell Biol, 2009, 41(5): 1034-1045. DOI: 10.1016/j.biocel.2008.09.018.

12.Wang F, Huang S, Chen Q, et al. Chemical characterisation and quantification of the major constituents in the Chinese herbal formula Jian-Pi-Yi-Shen pill by UPLC-Q-TOF-MS/MS and HPLC-QQQ-MS/MS[J]. Phytochem Anal, 2020, 31(6): 915-929. DOI: 10.1002/pca.2963.

13.Liu XH, Deng RY, Chen YL, et al. Jian-Pi-Yi-Shen formula improves adenine-induced chronic kidney disease via regulating tryptophan metabolism and aryl hydrocarbon receptor signaling[J]. Front Pharmacol, 2022, 13: 922707. DOI: 10.3389/fphar.2022.922707.

14.雷慧博, 余雅婷, 韩璐, 等. 基于HPLC-QQQ-MS技术探讨炮制对肉苁蓉中5个活性成分的含量影响[J]. 天然产物研究与开发, 2024, 36(1): 86-93. [Lei HB, Yu YT, Han L, et al. Influence of processing on the content of five active components in Cistanche tubulosa based on HPLC-QQQ-MS technology[J]. Natural Product Research and Development, 2024, 36(1): 86-93.] DOI: 10.16333/j.1001-6880.2024.1.010.

15.陈建真, 吕圭源, 叶磊, 等. 黄芪黄酮的化学成分与药理作用研究进展[J]. 医药导报, 2009, 28(10): 1314-1316. [Chen JZ, Lyu GY, Ye L, et al. Advances in research on chemical constituents and pharmacological effects of Astragalus Flavonoids[J]. Herald of Medicine, 2009, 28(10): 1314-1316.] DOI: 10.3870/yydb.2009.10.030.

16.Zhang L, Gong AGW, Riaz K, et al. A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide-induced anemic rats[J]. FEBS Open Bio, 2017, 7(3): 318-323. DOI: 10.1002/2211-5463.12146.

17.崔运浩. 黄芪甲苷、毛蕊异黄酮调控化疗性骨髓抑制小鼠骨髓干细胞机制研究[D]. 沈阳: 辽宁中医药大学, 2016. https://cdmd.cnki.com.cn/Article/CDMD-10162-1016309750.htm.

18.齐振强. 慢性肾脏病证素特征及黄芪丹参有效单体干预缺血损伤肾小球内皮细胞血管生成的机制研究[D]. 济南: 山东中医药大学, 2019. DOI: 10.27282/d.cnki.gsdzu.2019.000131.

19.Wang MQ, Hu R, Wang YJ, et al. Atractylenolide III attenuates muscle wasting in chronic kidney disease via the oxidative stress-mediated PI3K/AKT/mTOR pathway[J]. Oxid Med Cell Longev, 2019, 2019: 1875471. DOI: 10.1155/2019/1875471.

20.马超英, 彭春荣, 耿耘, 等. 大黄酸对内毒素血症小鼠保护作用的实验研究[J]. 中华中医药学刊, 2012, 30(2): 288-289. [Ma CY, Peng CR, Geng Y, et al. Experimental study on protective effects of rhein treating endotoxemia in rats[J]. Chinese Archives of Traditional Chinese Medicine, 2012, 30(2): 288-289.] DOI: 10.13193/j.archtcm.2012.02.66.machy.042.

21.刘锡强, 李丽, 田京伟. 迷迭香酸对大鼠心肌缺血损伤保护作用机制的探讨[J]. 中成药, 2011, 33(7): 1232-1234. [Liu  XQ, Li L, Tian JW. Exploration of the protective mechanism of Rosmarinic acid on myocardial ischemic injury in rats[J]. Chinese Traditional Patent Medicine, 2011, 33(7): 1232-1234.] DOI: 10.3969/j.issn.1001-1528.2011.07.039.

22.刘勇, 杨涛, 梁艳山, 等. 迷迭香酸通过抑制ROS/NLRP-3炎症小体信号通路对脑缺血再灌注小鼠的保护作用[J]. 重庆医学, 2023, 52(19): 2905-2911. [Liu Y, Yang T, Liang  YS, et al. Rosmarinic acid protected against brain injury in mice with cerebral ischemia reperfusion via oxidative stress and ROS/NLRP-3 signal pathway inhibition[J]. Chongqing Medical Journal, 2023, 52(19): 2905-2911.] DOI: 10.3969/j.issn.1671-8348.2023.19.005.

23.冯科冉, 李伟霞, 王晓艳, 等. 丹参化学成分、药理作用及其质量标志物(Q-Marker)的预测分析[J]. 中草药, 2022, 53(2): 609-618. [Feng KR, Li WX, Wang XY, et al. Chemical components and pharmacological action for Salviae Miltiorrhizae Radix et Rhizoma and predictive analysis on quality markers[J]. Chinese Traditional and Herbal Drugs, 2022, 53(2): 609-618.] DOI: 10.7501/j.issn.0253-2670.2022.02.031.

24.Zhou J, Zhang L, Zheng B, et al. Salvia miltiorrhiza bunge exerts anti-oxidative effects through inhibiting KLF10 expression in vascular smooth muscle cells exposed to high glucose[J]. J Ethnopharmacol, 2020, 262: 113208. DOI: 10.1016/j.jep.2020.113208.

25.舒菁菁, 李菲, 董雅芬, 等. 丹参素药理作用及机制的研究进展[J]. 药学实践杂志, 2012, 30(4): 266-268, 298. [Shu JJ, Li F, Dong YF, et al. Progress on the pharmacological actions and mechanism of Danshensu[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(4): 266-268, 298.] DOI: 10.3969/j.issn.1006-0111.2012.04.006.

26.张珊. 基于血管正常化探讨丹参调控肿瘤血管和下肢缺血疾病血管的作用及机制[D]. 南京: 南京中医药大学, 2022.  DOI: 10.27253/d.cnki.gnjzu.2022.000031.

27.Zhang GM, Cui GH, Tong SX, et al. Salvianolic acid A alleviates the renal damage in rats with chronic renal failure[J]. Acta Cir Bras, 2019, 34(2): e201900204. DOI: 10.1590/s0102-86502019 00204.

28.杨曙东, 易无庸, 唐新征, 等. 健脾益肾方治疗慢性肾功能衰竭营养不良40例临床研究[J]. 湖南中医药导报, 2004, 10(7): 3-5, 16. [Yang SD, Yi WY, Tang XZ, et al. Clinical study of jianpiyishen decoction for the treatment of 40 cases of malnutrition caused by chronic renal failure[J]. Guiding Journal of Traditional Chinese Medicine and Pharmacy, 2004, 10(7): 3-5, 16.] DOI: 10.13862/j.cnki.cn43-1446/r.2004.07.002.

29.Liu XH, Deng RY, Wei X et al. Jian-Pi-Yi-Shen formula enhances perindopril inhibition of chronic kidney disease progression by activation of SIRT3, modulation of mitochondrial dynamics, and antioxidant effects[J]. Biosci Rep, 2021, 41(10): BSR20211598. DOI: 10.1042/BS R20211598.

30.Zhou FY, Zou XH, Zhang J, et al. Jian-Pi-Yi-Shen formula ameliorates oxidative stress, inflammation, and apoptosis by activating the Nrf2 signaling in 5/6 nephrectomized rats[J]. Front Pharmacol, 2021, 12: 630210. DOI: 10.3389/fphar.2021.630210.

31.Chen JP, Gong AGW, Liu XY, et al. A Chinese herbal decoction, Jian-Pi-Yi-Shen, regulates the expressions of erythropoietin and pro-inflammatory cytokines in cultured cells[J]. BMC Complement Altern Med, 2018, 18(1): 119. DOI: 10.1186/s12906-018-2146-4.